Pfizer, reportedly working with Goldman Sachs, is considering selling its hospital drugs unit while facing pressure from ...

Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...

Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...

Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several preclinical ...

Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...

Diverge, a startup helping Medicaid members access care, raised $52 million led by Alphabet's GV. The company, launched in ...

AstraZeneca announces $2 billion investment to create 1,000 new US jobs, adding to previous $1.5 billion commitment. The $3.5 ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

Trace Neuroscience, a startup spun out of Maze Therapeutics' pipeline, broke cover Tuesday morning with $101 million in ...

Bayer CEO Bill Anderson affirmed plans to manage Xarelto's generic competition decline, as shares hit record low following Q3 ...

AstraZeneca CEO Pascal Soriot affirms commitment to China despite investigation involving China president Leon Wang and other employees. Wang, who reported directly to Soriot, and former AstraZeneca ...

Apollo Therapeutics will pay $12M upfront and up to $926M in milestone payments to Sunshine Lake Pharma for worldwide rights (excluding China) to their FGF21/GLP-1 dual receptor agonist ...